Keyphrases
Maintenance Therapy
100%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
100%
Clinical Trials
42%
Pemetrexed
42%
Erlotinib
42%
Initial Treatment
28%
Lung Cancer
14%
Expert Opinion
14%
Survival Benefit
14%
Docetaxel
14%
Progression-free Survival
14%
Bevacizumab
14%
Continuation Maintenance
14%
Switch Maintenance
14%
Molecular Targeted Agents
14%
Area Cover
14%
Clinical Strategies
14%
Gemcitabine
14%
Gefitinib
14%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Clinical Trial
75%
Pemetrexed
75%
Erlotinib
75%
Progression Free Survival
25%
Chemotherapy
25%
Lung Cancer
25%
Gemcitabine
25%
Docetaxel
25%
Bevacizumab
25%
Gefitinib
25%
Medicine and Dentistry
Maintenance Therapy
100%
Non Small Cell Lung Cancer
100%
Clinical Trial
42%
Pemetrexed
42%
Erlotinib
42%
Lung Cancer
14%
Progression Free Survival
14%
Gemcitabine
14%
Bevacizumab
14%
Chemotherapy
14%
Translating (Language)
14%
Docetaxel
14%
Gefitinib
14%
Nursing and Health Professions
Erlotinib
42%
Pemetrexed
42%
Maintenance Chemotherapy
14%
Chemotherapy
14%